These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16531258)

  • 1. Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia.
    Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
    Haematologica; 2006 Mar; 91(3):348-55. PubMed ID: 16531258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization.
    Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
    Immunobiology; 2005; 210(2-4):249-57. PubMed ID: 16164032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting.
    Houtenbos I; Westers TM; Dijkhuis A; de Gruijl TD; Ossenkoppele GJ; van de Loosdrecht AA
    Clin Cancer Res; 2007 Jan; 13(1):307-15. PubMed ID: 17170077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells.
    Draube A; Beyer M; Wolf J
    Eur J Haematol; 2008 Oct; 81(4):281-8. PubMed ID: 18573171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia.
    Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
    Immunobiology; 2006; 211(6-8):677-85. PubMed ID: 16920506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
    van de Loosdrecht AA; van den Ancker W; Houtenbos I; Ossenkoppele GJ; Westers TM
    Handb Exp Pharmacol; 2009; (188):319-48. PubMed ID: 19031033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can leukemia-derived dendritic cells generate antileukemia immunity?
    Rosenblatt J; Avigan D
    Expert Rev Vaccines; 2006 Aug; 5(4):467-72. PubMed ID: 16989627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
    Greiner J; Döhner H; Schmitt M
    Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cell vaccines in acute leukaemia.
    Duncan C; Roddie H
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):521-41. PubMed ID: 18790453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental production of clinical-grade dendritic cell vaccine for acute myeloid leukemia.
    Tan YF; Sim GC; Habsah A; Leong CF; Cheong SK
    Malays J Pathol; 2008 Dec; 30(2):73-9. PubMed ID: 19291915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy.
    Royer PJ; Bougras G; Ebstein F; Leveque L; Tanguy-Royer S; Simon T; Juge-Morineau N; Chevallier P; Harousseau JL; Gregoire M
    Exp Hematol; 2008 Mar; 36(3):329-39. PubMed ID: 18207305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dendritic cell-based therapeutic vaccination for acute myeloid leukemia].
    Anguille S; Van Tendeloo V; Berneman Z
    Bull Cancer; 2012 Jun; 99(6):635-42. PubMed ID: 22641288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Back to basics: in search of the optimal dendritic cell for vaccination in AML.
    van den Ancker W; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
    Leuk Res; 2008 Nov; 32(11):1641-3. PubMed ID: 18468681
    [No Abstract]   [Full Text] [Related]  

  • 14. Adhesion capacity and integrin expression by dendritic-like cells generated from acute myeloid leukemia blasts by calcium ionophore treatment.
    Sadovnikova E; Parovichnikova EN; Semikina EL; Kopiltsova EA; Svinareva DA; Belkin VM; Torubarova NA; Savchenko VG
    Exp Hematol; 2004 Jun; 32(6):563-70. PubMed ID: 15183897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current progress in the development of a cell-based vaccine for the immunotherapy of acute myeloid leukemia.
    Klammer M; Roddie PH
    Expert Rev Vaccines; 2006 Apr; 5(2):211-22. PubMed ID: 16608421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia.
    Schmitt A; Li L; Giannopoulos K; Greiner J; Reinhardt P; Wiesneth M; Schmitt M
    Transfusion; 2008 May; 48(5):861-70. PubMed ID: 18208411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
    Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonleukemic myeloid dendritic cells obtained from autologous stem cell products elicit antileukemia responses in patients with acute myeloid leukemia.
    Serrano-López J; Sanchez-Garcia J; Serrano J; Alvarez-Rivas MA; Garcia-Castellano JM; Roman-Gomez J; de la Rosa O; Herrera-Arroyo C; Torres-Gomez A
    Transfusion; 2011 Jul; 51(7):1546-55. PubMed ID: 21303373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
    Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
    Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.
    Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR
    Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.